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A b s t r a c t
Background: Cardiomyocyte death facilitates the pathological process underlying ischaemic heart diseases, such as myocardial 
infarction. Emerging evidence suggests that microRNAs play a critical role in the pathological process underlying myocardial 
infarction by regulating cardiomyocyte apoptosis. However, the relevance of miR-130a in regulating cardiomyocyte apoptosis 
and the underlying mechanism are still uncertain. 
Aim: We sought to explore the regulatory effect of miR-130a on hypoxic cardiomyocyte apoptosis. 
Methods: The expression of miR-130a was measured by quantitative reverse transcription polymerase chain reaction 
(qRT-PCR). Cell survival was determined by the MTT assay. The lactate dehydrogenase (LDH) assay was performed to deter-
mine the severity of hypoxia-induced cell injury. Apoptosis was assessed via caspase-3 analysis. Protein expression level was 
determined by Western blotting. The genes targeted by miR-130a were predicted using bioinformatics and were validated 
via the dual-luciferase reporter assay system.
Results: We found that miR-130a expression was greatly increased in hypoxic cardiac myocytes, and that the downregulation 
of miR-130a effectively shielded cardiac myocytes from hypoxia-triggered apoptosis. In bioinformatic analysis the Smad4 gene 
was predicted to be the target of miR-130a. This finding was validated through the Western blot assay, dual-luciferase reporter 
gene assay, and qRT-PCR. MiR-130a inhibition significantly promoted the activation of Smad4 in hypoxic cardiomyocytes. Inter-
estingly, knockdown of Smad4 markedly reversed the protective effects induced by miR-130a inhibition. Moreover, we found 
that the inhibition of miR-130a promoted the activation of transforming growth factor-b1 signalling. Blocking of Smad4 signal-
ling significantly abrogated the protective effects of miR-130a inhibition.
Conclusions: The findings indicate that inhibition of miR-130a, which targets the Smad4 gene, shields cardiac myocytes from 
hypoxic apoptosis. This study offers a novel perspective on the molecular basis of hypoxia-induced cardiomyocyte apoptosis 
and suggests a possible drug target for the treatment of myocardial infarction.
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INTRODUCTION
Heart disease is a growing problem [1]. Despite significant 
progress in the treatment of heart disease with medication, 
a dismal general prognosis with high mortality still remains [2]. 
Ischaemia-reperfusion injury aggravates morbidity and in-
creases mortality among a considerable variety of diseases, 
including myocardial infarction (MI) [3]. The heart is well 
known for its delicacy, having little capacity for regeneration 
and rehabilitation. The heart is also known to respond to both 
progressive and acute stressors.
The Smad family of proteins were initially identified as key 
downstream signal transducers in the transforming growth fac-
tor-b1 (TGF-b1) signalling pathway. Overexpression of a domi-
nant negative Smad3 mutant or of Smad7, both of which im-
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pair Smad-mediated signal transduction, inhibits TGF-b1-de-
pendent apoptosis [4]. TGF-b receptors activate Smad-inde-
pendent pathways that do not only regulate Smad signalling 
but also allow Smad-independent TGF-b responses [5]. 
Smad4 is as an essential mediator of the TGF-b signalling 
pathway, and dysregulated TGF-b signalling is linked with 
thoracic aortic aneurysms [6]. Furthermore, miR-146b-5p has 
been shown to directly target Smad4 and thereby negatively 
regulate the TGF-b signalling pathway [7]. In a recent study, 
Smad4 was found to play an important role in heart devel-
opment [8]. Smad4 is important in the TGF-b pathway, and 
it plays a key role as a transcription factor and inhibits cell 
growth after TGF-b1 stimulation [9].
Recently, microRNAs (miRNAs) have been shown to regu-
late complex molecular networks through feedback mecha-
nisms [10]. miRNAs are a type of small, highly conserved 
non-coding RNA, and endogenous miRNAs typically have 
between 18 and 22 nucleotides. They participate in the regu-
lation of cell proliferation, differentiation, and death by target-
ing the 3’-UTR of specific mRNA at the post-transcriptional 
level for degradation or translation repression [11]. Recent 
years have seen an increase in the interests of scholars in the 
pathological role that miRNAs may play in heart diseases [12].
A number of miRNA-based therapies have undergone 
pre-clinical and clinical trials [11]. miR-130a has previously 
been reported to be an apoptosis-associated miRNA [13]. 
Its expression was detected in embryo heart tissues and 
was actively involved in heart growth. In embryonic cardiac 
myocytes, upregulated miR-130a expression may lead to an 
atrophied ventricular muscle and an irregular heart structure 
[14]. In addition, it was recorded that miR-130a expression 
was decreased in various kinds of heart disease models [15]. 
However, whether miR-130a is associated with apoptosis 
of cardiac myocytes is still unclear. In addition, it has been 
shown that miR-130a expression is downregulated in various 
ischaemia/reperfusion (I/R) models. However, the exact role 
of miR-130a in the pathogenesis of I/R injury, particularly its 
association with autophagy, has not yet been fully elucidated.
In the present study, the expression of miR-130a, and the 
role of miR-130a in myocardial injury and apoptosis induced 
by hypoxia/reoxygenation (H/R) in cultured H9C2 rat cardio-
myocytes were examined. The results show that miR-130a 
initiates H/R-induced apoptosis of cardiomyocytes by targeting 




Rat myocardium-derived H9C2 and HEK293 cells were 
obtained from ATCC (VA, USA) and cultured in Dulbecco’s 
modified Eagle’s medium (Gibco BRL Inc., Waltham, MA, 
USA) with 10% foetal bovine serum (FBS) (Gibco BRL Inc., 
Waltham, MA, USA) and 1% penicillin (P/S; Invitrogen Inc., 
Waltham, MA, USA). The cells were incubated in a humidified 
CO2 incubator (concentration: 5%) at a temperature of 37°C. 
Cell treatment
Cells were subjected to hypoxia for 24 h at 37°C in 1% O2, 
94% N2, and 5% CO2 using a modular incubator (Model 
3131; Forma; Thermo Fisher Scientific, Inc., Waltham, MA, 
USA). Subsequently, reoxygenation (5% CO2; 37°C, 95% air 
[79% N2/21% O2]) was performed for 24 h. Cells cultured 
under normoxic conditions served as a control. Ischaemia and 
reperfusion were simulated by culturing the cells in DMEM 
containing 1% or 10% FBS, respectively.
Quantitative reverse transcription polymerase 
chain reaction (qRT-PCR) 
Total RNA was extracted from cardiac myocytes using TRIzol 
Reagent (Invitrogen) following the manufacturer’s manu-
als. We carried out reverse transcription (RT) to synthesise 
cDNA with 20 mL ddH2O, 4 mL 5 × Mix, and 500 ng/μL 
RNA. The temperature conditions for RT were 37°C, 50°C, 
and 98°C for 15 min, 5 min, and 5 min, respectively. qPCR 
was carried out using the QuantiNova SYBR Green kit (Qia-
gen, Hilden, Germany). We used Primer Premier 5 to design 
the primers. The PCR primer sequences were: miR-130a, 
5’-CAGUGCAAUGUUAAAAG-3’; GAPDH forward, 5’-CCT-
CAAGATTGTCAGCAAT-3’ and reverse, 5’-CCATCCACA-
GTCTTCTGAGT-3’. The reaction involved denaturation at 
a temperature of 95°C for 1 min and 15 s, followed by 
40 cycles of incubation at 72°C and 60°C for 30 s and 15 s, 
respectively, followed by another 1 min reaction at 72°C. 
A melting curve analysis was performed in the range 65°C to 
95°C at 0.2°C intervals. The 2−DDCq method was adopted for 
the calculation of the target gene’s expression level. Negative 
controls were prepared with ddH2O. All experiments were 
done in triplicate. 
3-(4, 5-dimethylthiazol-2-yl)-2,  
5-diphenyltetrazolium bromide (MTT) assay
Cells were plated in 96-well plates at a density of 1 × 103 
cells/well and incubated overnight. They were subsequently 
treated with 20 μL of MTT (Sigma-Aldrich, St. Louis, MO, 
USA; 5 mg/mL). The supernatants were discarded after 4 h, 
and 200 μL of dimethyl sulfoxide (SigmaAldrich, St. Louis, 
MO, USA) was added to each well and incubated for 15 min 
to dissolve the formazan crystals in the living cells. The ab-
sorbance at 490 nm was measured with a microplate reader 
(Bio-Tek Instruments, Winooski, VT, USA).
Lactate dehydrogenase (LDH) assay
Cells were lysed using 0.2% Triton X-100 (Sigma-Aldrich, St. 
Louis, MO, USA). Supernatants were harvested after centrifu-
gation and then incubated with pyruvate and nicotinamide 
adenine dinucleotide hydrogen (Roche Applied Science, Indi-
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anapolis, IN, USA) for 30 min. The absorbance at 530 nm was 
detected by a microplate reader (Bio-Rad, Berkeley, CA, USA).
Caspase-3 activity assay
Cells were lysed, and protein concentration was meas-
ured. Protein samples (100 μg) were treated with 10 μL of 
Ac-DEVD-pNA (Roche Applied Science) for 4 h at 37°C. The 
absorbance at 405 nm was measured with a microplate reader 
(Bio-Tek Instruments, Burlington, VT, USA).
Western blot assay
Myocardial cells were suspended in 1% NP-40 buffer for 
30 min. Protein concentration was measured via the deter-
gent compatible DC Protein Assay (Bio-Rad; Hercules, CA, 
USA) method after the cells were centrifuged at 12,000 × g 
for 20 min at 4°C. Thirty micrograms of protein lysate was 
loaded onto 10% SDS-PAGE gels, and electrophoresis was 
run at 140 mV for 1 h. Afterwards, the proteins on the gels 
were transferred onto nitrocellulose membranes at 220 mV 
and 300 mA for 3 h. The nitrocellulose membranes were then 
soaked in 5% skimmed milk for 1 h before being incubated 
with rat anti-Smad4 primary antibody (1:1000; Santa Cruz 
Biotechnology, sc-73040) and anti-b-actin primary antibody 
(1:2000; Santa Cruz Biotechnology) separately for 14 h at 
4°C. Next, the membrane was incubated in goat anti-mouse 
secondary antibody (1:5000 Santa Cruz Biotechnology) for 
1 h in normal temperature conditions. The Western blot was 
mapped by the enhanced chemiluminescence (ECL) method. 
Protein bands were analysed via Image J software (National 
Institutes of Health, Bethesda, MD, USA).
Luciferase reporter assessment
We used TargetScan software (Whitehead Institute for Bio-
medical Research, Cambridge, MA, USA) to screen for poten-
tial target sequences of miR-130a in the 3’-UTR of Smad4. The 
wild type and mutated sequences are as follows: wild 
type Smad4-3’-UTR: 5’-AUUUUGCACUG-3’ and mutant 
Smad4 3’-UTR: 5’-AGUCUACGCAG-3’. The sequences were 
amplified and cloned into Promega’s psiCHECK™ (Promega 
Corporation, Madison, WI, USA) reporter plasmids to obtain 
the plasmids wt-Smad4-3’-UTR and mut-Smad4-3’-UTR. The 
plasmids were then co-transfected with miR-130a/negative 
control (NC) mimics into HEK-293 cells. The results of the 
experiments were analysed following the manufacturer’s op-
eration manual. Each experiment was carried out in triplicate. 
Bioinformatics
The potential target genes of miR-130a were predicted using 
TargetScan software.
Statistical analysis 
Data were recorded as mean ± standard deviation. GraphPad 
Prism 5 (GraphPad Software, San Diego, CA, USA) was em-
ployed for statistical analysis. The t test was used for pair-wise 
comparison, and variance was calculated for multiple com-
parisons. P < 0.05 (indicated by an asterisk) was considered 
to suggest a significant difference.
RESULTS
miR-130a was considerably increased  
in hypoxic cardiomyocytes
To determine whether hypoxia affects miR-130a expression 
in cardiomyocytes, we first examined the level of miR-130a 
expression in response to hypoxia via qRT-PCR. Data showed 
that the miR-130a expression in hypoxic cardiomyocytes 
was greatly increased compared to that in control normoxic 
cardiomyocytes (Fig. 1A), indicating the important role of 
miR-130a in hypoxic cardiomyocytes.
Inhibition of miR-130a suppresses  
hypoxia-induced apoptosis
The biological role of miR-130a in hypoxic cardiomyocytes 
was determined. The expression of miR-130a was suppressed 
in hypoxic cardiomyocytes by transfecting an miR-130a 
inhibitor (Fig. 1B). The effect of the miR-130a inhibitor on 
cell survival was determined by the MTT assay. The results 
indicated that inhibition of miR-130a expression consider-
ably improved the survival rate of impaired, hypoxic cardio-
myocytes (Fig. 1C). The LDH assay showed that inhibition of 
miR-130a markedly inhibited hypoxia-induced cell injury in 
cardiomyocytes (Fig. 1D). 
We then evaluated the impact of miR-130a inhibition 
on apoptosis via caspase-3 analysis. The results indicated that 
inhibition of miR-130a could lead to a considerable decline 
in caspase-3 activity in hypoxic cardiomyocytes (Fig. 2A) 
and to an increase in the expression of the anti-apoptotic 
protein Bcl-2 (Fig. 2B). In general, the results suggested that 
inhibition of miR-130a inhibited hypoxia-induced apoptosis 
of cardiac myocytes.
Smad4 as a target gene of miR-130a
To further explore the mechanism that enables miR-130a 
inhibition to suppress hypoxia-induced apoptosis, we pre-
dicted the target genes of miR-130a via a bioinformatic 
analysis. Among the identified putative target genes, Smad4, 
a gene important for cell survival in cardiomyocytes, showed 
promising characteristics. The binding site for miR-130a at 
the 3’-UTR of Smad4 is shown in Figure 3A. To determine 
whether miR-130a directly targets the 3’-UTR of Smad4, we 
performed a dual-luciferase reporter assay. We found that 
overexpression of miR-130a considerably inhibited the activ-
ity of the luciferase reporter from the vector containing the 
3’-UTR of Smad4 (Fig. 3B). However, as shown in Figure 3B, 
miR-130a overexpression had little influence on the activity 
of the reporter from the vector bearing the mutated 3’-UTR of 
Smad4, implying that miR-130a directly targeted the 3’-UTR 
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Figure 1. MiR-130a expression in hypoxic cardiomyocytes. H9C2 cells were exposed to hypoxic conditions for 24 h and then 
harvested for quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis; p < 0.05 as compared with cells 
cultured in normoxic conditions. A. Inhibition of miR-130a increased the survival rate of hypoxic cardiomyocytes. H9C2 cells were 
transfected with either the miR-130a inhibitor or negative control (NC) for 24 h and then exposed to hypoxia for another 24 h. 
B. miR-130a expression was measured through qRT-PCR analysis. Cell survival of cardiomyocytes was determined by MTT (C)  
and lactate dehydrogenase (LDH) (D) analysis. Data are presented as mean ± standard deviation from three independent  
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Figure 2. Inhibition of miR-130a reduces apoptosis triggered by hypoxia in myocardial cells. H9C2 cells were transfected with 
miR-130a inhibitor/negative control (NC) for 24 h and then exposed to hypoxia for another 24 h; A. Apoptosis was assessed 
using the caspase-3 activity assay; B. Protein expression level was measured through a Western blot assay. Data are presented as 
mean ± standard deviation from three independent experiments; *p < 0.05 as compared with the control group; inh. — inhibitor; 
OD — optical density
Figure 3. miR-130a targets the 3’-UTR of Smad4. A. Sequence 
alignment of miR-130a and the 3’-UTR of Smad4; B. Dual-luci-
ferase reporter gene assay. HEK293 cells were transfected with 
miR-130a mimics as well as a luciferase reporter gene carrying 
either the wild type or a mutated form of the Smad4 3’-UTR 
and incubated for 48 h. Relative luciferase activities were 
measured through the dual luciferase reporter assay system. 
Data are presented as mean ± standard deviation from three 
independent experiments; *p < 0.05 as compared with the 
control group; NC — negative control
of Smad4. To further validate whether Smad4 is a direct target 
of miR-130a, we analysed the effect of inhibition of miR-130a 
on the expression of Smad4. The results showed that inhibi-
tion of miR-130a significantly promoted the expression of 
both Smad4 mRNA (Fig. 4A) and Smad4 protein (Fig. 4B). 
Overall, these results indicate that Smad4 is a direct target 
gene of miR-130a.
Inhibition of miR-130a upregulates  
the TGF-b signalling targeting Smad4 
To further investigate the molecular mechanisms underlying 
the regulation of hypoxia-induced apoptosis by miR-130a, we 
determined the effect of miR-130a inhibition on TGF-b signal-
ling. The results showed that TGF-b protein levels increased 
greatly upon miR-130a inhibition (Fig. 4C). Moreover, the 
expression levels of downstream target genes of the TGF-b sig-
nalling pathway, including Smad4, also significantly increased 
upon miR-130a inhibition. These results suggest that inhibition 
of miR-130a promotes the activation of TGF-b signalling.
Knockdown of miR-130a abolishes  
its protective impact
To confirm that TGF-b is involved in the induction of protec-
tive mechanisms against hypoxia, upon miR-130a inhibition, 
we silenced the expression of TGF-b gene while miR-130a 
was inhibited (Fig. 5A). Similarly, the increased protein levels 
of Smad4 induced by miR-130a inhibition were markedly 
decreased upon TGF-b silencing (Fig. 5B). As predicted, the 
protective effects of miR-130a inhibition against hypoxia-in-
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TGF-b silencing. Overall, these results suggest that miR-130a 
inhibition protects cardiomyocytes against hypoxia-induced 
apoptosis by promoting Smad4 expression.
To further verify whether the Smad4 signalling pathway 
is involved in miR-130a inhibition-induced protective effects 
against hypoxia, we blocked Smad4 signalling using RepSox 
and then assessed its effect on miR-130a inhibition-in-
duced protective effects. The results showed that blocking 
Smad4 signalling significantly decreased the protective effects 
of miR-130a inhibition against hypoxia-induced apoptosis 
(Fig. 6A, B), implying that this protection is conferred by 
miR-130a inhibition through the regulation of the Smad4 sig-
nalling pathway.
DISCUSSION
In recent studies, miRNAs have been detected in body fluids, 
including urine, saliva, and plasma [16]. Numerous miRNAs 
are dysregulated in MI, serving as potential targets for the de-
A B
C
Figure 4. Inhibition of miR-130a promotes Smad4 expres-
sion. H9C2 cells were transfected with either miR-130a inhi- 
bitor or negative control (NC) for 24 h and then exposed to 
hypoxia for another 24 h. The Smad4 mRNA (A) and protein 
(B) expression levels were measured by quantitative reverse 
transcription polymerase chain reaction and Western blot 
analysis, respectively; C. The transforming growth factor-b 
(TGF-b) protein level was measured by Western blot analysis.  
Data are presented as mean ± standard deviation from three 
independent experiments; *p < 0.05 as compared with the 
control group; inh. — inhibitor
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Figure 5. Knockdown of transforming growth factor-b (TGF-b) abolishes the protective effects of miR-130a inhibition. H9C2 cells 
were co-transfected with an miR-130a inhibitor and a TGF-b siRNA for 24 h and then exposed to hypoxia for another 24 h. Protein 
expression levels of TGF-b (A) and Smad4 (B) were measured by Western blot analysis; C. Cell injury was assessed by lactate 
dehydrogenase (LDH) assay; D. Apoptosis was evaluated using the caspase-3 activity assay; *p < 0.05; NC — negative control;  
OD — optical density
velopment of miRNA-based therapy. A good understanding of 
the role of miRNAs in regulating cardiomyocyte apoptosis will 
help the development of novel therapies for MI. Overall, the 
limited amount of evidence supporting the use of miRNAs in 
clinical settings calls for more epidemiological investigation to 
translate their molecular implications into clinical applications 
as biomarkers of disease severity, diagnosis, and ultimately 
prognosis. In the present study, we found that miR-130a ex-
pression was greatly increased in hypoxic cardiac myocytes, 
and the downregulation of miR-130a expression effectively 
shielded cardiac myocytes from hypoxia-triggered apopto-
sis. We also showed that the Smad4 gene was the target of 
miR-130a. The inhibition of miR-130a significantly promoted 
the activation of Smad4 in hypoxic cardiomyocytes. Block-
ing of Smad4 significantly abrogated the protective effects of 
miR-130a inhibition. Our findings indicate that inhibition of 
miR-130a shields cardiac myocytes from hypoxic apoptosis 
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Figure 6. Blocking Smad4 signalling abolishes the protective effects of miR-130a inhibition. H9C2 cells were transfected with  
an miR-130a inhibitor in the presence of 100 nM RepSox, incubated for 24 h, and then exposed to hypoxia for another 24 h.  
A. Cell injury was assessed by lactate dehydrogenase (LDH) assay; B. Apoptosis was evaluated by a caspase-3 activity assay. Data  
are presented as mean ± standard deviation from three independent experiments; *p < 0.05 as compared with the control group;  
DMSO — dimethyl sulfoxide; NC — negative control; OD — optical density
Through bioinformatic analysis and the dual-luciferase 
reporter assay, we identified Smad4 as a potential target gene 
of miR-130a. Unlike other Smads, Smad4, which is active in 
signalling, influences the interaction between bone morpho-
genetic proteins (BMPs) and TGF-b. Patients with hereditary 
disorders that arise due to changes in TGF-b or in the BMP 
family of genes seldom demonstrate cardiovascular disorders 
that correspond to the affected pathway [17]. Smad4 muta-
tions separate family members into various disease groups 
such as aortopathy, juvenile polyposis syndrome, and mitral 
valve disorder [18]. Smad4 is a tumour suppressor that trans-
duces TGF-b signalling and regulates genomic stability [19]. 
The expression of SMADs in the ischaemic cardiac muscles 
changes significantly following MI, suggesting a close relation-
ship between Smad4 proteins and heart remodelling. Moreo-
ver, it is known that the expression of Smad4 is regulated by 
TGF-b and BMPs [20]. Smad4 is also involved in the regulation 
of MI. Based on these findings, regulating the expression of 
Smad4 proteins by targeting TGF-b and BMP in the ischaemic 
myocardium may be considered as a potential treatment for 
MI. In this study it has been revealed that miR-130a inhibition 
causes de-repression of Smad4 and therefore attenuation of 
cardiomyocyte apoptosis (Smad4 is a protective agent for 
myocardial cells). 
Overall, our research implied that miR-130a regulates 
cardiomyocyte apoptosis. We found that miR-130a inhibi-
tion shielded cardiac myocytes from apoptosis triggered by 
hypoxia through the upregulation of Smad4 expression and 
activation of Smad4 signalling. Our study provides a novel 
understanding of the molecular mechanism of cardiomyocyte 
death triggered by hypoxia and offers a possible target in the 
treatment of MI. However, the precise effect of Smad4 inhibi-
tion on the treatment of MI needs to be further investigated 
in animal models.
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Hotel Holiday Inn Kraków, ul. Wielopole 4
Cykl konferencji „Kardiologia Prewencyjna” to multidyscyplinarne spotkania o ugruntowanej renomie, na które  
zapraszamy nie tylko kardiologów, ale także internistów i lekarzy rodzinnych. Wykładowcami będą najlepsi polscy 
eksperci. W czasie tegorocznej Konferencji zostaną omówione najnowsze doniesienia z zakresu szeroko rozumianej 
kardiologii prewencyjnej. W programie Konferencji znajdą się też prezentacje najnowszych wyników dużych polskich 
projektów badawczych i innych doniesień naukowych z krajowych i zagranicznych ośrodków naukowych.  
Ponadto w sposób przystępny i praktyczny zostaną podsumowane najnowsze zmiany w diagnostyce i leczeniu  
chorób układu krążenia. Zapraszamy do udziału w Konferencji.
www.kardiologiaprewencyjna.eu
www.kardiologiapolska.pl
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